sevoflurane piramal (sevoflurane) innöndunargufa, gegndreyptur stabbi 100 %
piramal critical care b.v. - sevofluranum inn - innöndunargufa, gegndreyptur stabbi - 100 %
symbicort turbuhaler (lyfjaver) noregur innöndunarduft 160/4,5 míkróg/skammt
lyfjaver ehf. - budesonidum inn; formoterolum inn fúmarat - innöndunarduft - 160/4,5 míkróg/skammt
symbicort turbuhaler innöndunarduft 160/4,5 míkróg/skammt
astrazeneca a/s - budesonidum inn; formoterolum fúmarat - innöndunarduft - 160/4,5 míkróg/skammt
symbicort forte turbuhaler innöndunarduft 320/9 míkróg/skammt
astrazeneca a/s - budesonidum inn; formoterolum fúmarat - innöndunarduft - 320/9 míkróg/skammt
symbicort mite turbuhaler innöndunarduft 80/4,5 míkróg/skammt
astrazeneca a/s - budesonidum inn; formoterolum fúmarat - innöndunarduft - 80/4,5 míkróg/skammt
sevoflurane baxter innöndunargufa, gegndreyptur stabbi 100 %
baxter medical ab* - sevofluranum inn - innöndunargufa, gegndreyptur stabbi - 100 %
salmeterol/fluticasone neutec (salmeterol/fluticasone wellnex) innöndunarduft, afmældir skammtar 50 míkróg/100 míkróg/skammt
neutec inhaler ireland limited - salmeterolum xínafóat; fluticasonum própíónat - innöndunarduft, afmældir skammtar - 50 míkróg/100 míkróg/skammt
salmeterol/fluticasone neutec (salmeterol/fluticasone wellnex) innöndunarduft, afmældir skammtar 50 míkróg/250 míkróg/skammt
neutec inhaler ireland limited - salmeterolum xínafóat; fluticasonum própíónat - innöndunarduft, afmældir skammtar - 50 míkróg/250 míkróg/skammt
aservo equihaler
boehringer ingelheim vetmedica gmbh - ciclesonide - Öndunarfærum, Önnur lyf fyrir veikindi öndunarvegi sjúkdómum, inhalants - hestar - til að lina klínískum merki um alvarlega hrossum asma (áður þekktur sem endurtekinn Öndunarvegi – (rao), sumar haga tengslum endurtekin Öndunarvegi – (spa-rao)).
nyxthracis (previously obiltoxaximab sfl)
sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - Ónæmiskerfið sera og mótefni, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.